{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:04:28Z","timestamp":1791921868281,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.esmoop.2023.101197","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T20:42:58Z","timestamp":1679949778000},"page":"101197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe"],"prefix":"10.1016","volume":"8","author":[{"given":"M.","family":"de With","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sadlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cecchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Haufroid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Joerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.H.N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.R.","family":"Largiad\u00e8r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2023.101197_bib1","unstructured":"European Medicines Agency (EMA). Summary of product characteristics (SmPC) Capecitabine Xeloda. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeloda-epar-product-information_en.pdf. Accessed March 20, 2023."},{"key":"10.1016\/j.esmoop.2023.101197_bib2","unstructured":"Medicines Evaluation Board (MEB). Summary of product characteristics (SmPC) fluorouracil 50 mg\/ml solution for injection or infusion. Available at https:\/\/www.geneesmiddeleninformatiebank.nl\/smpc\/h100701_smpc.pdf. Accessed March 20, 2023."},{"key":"10.1016\/j.esmoop.2023.101197_bib3","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.101197_bib4","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101197_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(07)61086-1","article-title":"Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial","volume":"370","author":"Koopman","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2023.101197_bib6","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101197_bib7","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/onco.13967","article-title":"Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: A systematic review and meta-analysis","volume":"26","author":"Sharma","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2023.101197_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2019.09.028","article-title":"Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: a real-life evaluation in France","volume":"124","author":"Barin-Le Guellec","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.101197_bib9","first-page":"2899","article-title":"Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients","volume":"52","author":"Fleming","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2023.101197_bib10","first-page":"197","article-title":"Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion","volume":"50","author":"Harris","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2023.101197_bib11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/cpt.2069","article-title":"Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity: what are the options?","volume":"109","author":"Knikman","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2023.101197_bib12","unstructured":"European Medicines Agency (EMA). EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. 2020. Available at https:\/\/www.ema.europa.eu\/en\/news\/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine. Accessed March 20, 2023."},{"key":"10.1016\/j.esmoop.2023.101197_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2023.101197_bib14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.101197_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","article-title":"5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency","volume":"249","author":"Boisdron-Celle","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.esmoop.2023.101197_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175998","article-title":"New advances in DPYD genotype and risk of severe toxicity under capecitabine","volume":"12","author":"Etienne-Grimaldi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2023.101197_bib17","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2023.101197_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD\u22172A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101197_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00118","article-title":"Treatment algorithm for homozygous or compound heterozygous DPYD variant allele carriers with low-dose capecitabine","author":"Henricks","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2023.101197_bib20","article-title":"DPYD\u22177 as a predictor of severe fluoropyrimidine-related adverse events","volume":"6","author":"de With","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2023.101197_bib21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cpt.2667","article-title":"Dihydropyrimidine dehydrogenase deficiency and implementation of upfront DPYD genotyping","volume":"112","author":"White","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2023.101197_bib22","doi-asserted-by":"crossref","first-page":"e958","DOI":"10.1200\/OP.21.00874","article-title":"Survey of US medical oncologists' practices and beliefs regarding DPYD testing before fluoropyrimidine chemotherapy","volume":"18","author":"Koo","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.esmoop.2023.101197_bib23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cpt.2608","article-title":"Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study","volume":"112","author":"de With","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2023.101197_bib24","unstructured":"Orphanet. The portal for rare diseases and orphan drugs. In: French National Institute for Health and Medical Research. 2022. Available at https:\/\/www.orpha.net\/consor\/cgi-bin\/ClinicalLabs_Search_Simple.php?lng=EN&LnkId=15887&Typ=Gen&from=rightMenu. Accessed March 20, 2023."},{"key":"10.1016\/j.esmoop.2023.101197_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines","volume":"28","author":"Lunenburg","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.esmoop.2023.101197_bib26","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/17843286.2020.1870855","article-title":"Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur)","volume":"77","author":"Casneuf","year":"2022","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.esmoop.2023.101197_bib27","unstructured":"Dansk Selskab For Klinisk Biokemi. Test for aktivitet af dihydropyrimidin dehydrogenase forud for behandling med 5-fluorouracil- (i.v.), capecitabin- og tegafurholdige pr\u00e6parater. Available at https:\/\/dskb.dk\/wp-content\/uploads\/2021\/04\/NationalkonsensusDPD-_17.03marts2021.pdf. Accessed March 20, 2023."},{"key":"10.1016\/j.esmoop.2023.101197_bib28","unstructured":"National Health Service England. Clinical Commissioning Urgent Policy Statement: Pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies. 2020. Available at https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2020\/11\/1869-dpyd-policystatement.pdf. Accessed March 20, 2023."},{"key":"10.1016\/j.esmoop.2023.101197_bib29","unstructured":"terveysportti. Kolorektaalisy\u00f6v\u00e4n kansalliset hoitosuositukset. 2022. Available at https:\/\/www.terveysportti.fi\/apps\/ltk\/article\/hsu00007?toc=507. Accessed March 20, 2023."},{"key":"10.1016\/j.esmoop.2023.101197_bib30","unstructured":"A cura del Gruppo di Lavoro di AIOM - SIF. Raccomandazioni per analisi farmacogenetiche. 2020. Available at https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/10\/2019_Raccanalisi-farmacogenetiche_v26.3.2020.pdf. Accessed March 20, 2023."},{"key":"10.1016\/j.esmoop.2023.101197_bib31","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12094-021-02708-4","article-title":"Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines","volume":"24","author":"Garc\u00eda-Alfonso","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.esmoop.2023.101197_bib32","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2020.20375","article-title":"Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy","volume":"150","author":"Hamzic","year":"2020","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.esmoop.2023.101197_bib33","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1159\/000510258","article-title":"Dihydropyrimidine dehydrogenase testing prior to treatment with 5-fluorouracil, capecitabine, and tegafur: a consensus paper","volume":"43","author":"W\u00f6rmann","year":"2020","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.esmoop.2023.101197_bib34","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Recherche de d\u00e9ficit en dihydropyrimidine d\u00e9shydrog\u00e9nase en vue de pr\u00e9venir certaines toxicit\u00e9s s\u00e9v\u00e8res survenant sous traitement comportant des fluoropyrimidines.\u00a02018."},{"key":"10.1016\/j.esmoop.2023.101197_bib35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/pme.14.1","article-title":"Cancer pharmacogenomics, adoption by oncologists and patient benefit","volume":"11","author":"Dressler","year":"2014","journal-title":"Per Med"},{"key":"10.1016\/j.esmoop.2023.101197_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.885259","article-title":"Clinical implementation of DPYD pharmacogenetic testing to prevent early-onset fluoropyrimidine-related toxicity in cancer patients in Switzerland","volume":"13","author":"Begr\u00e9","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923004192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923004192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:45Z","timestamp":1761856185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923004192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2059702923004192"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101197","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101197","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101197"}}